Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.

By M. Collins, Filip Bednar, Yaqing Zhang, J. Brisset, S. Galban, C. Galbán, Sabita Rakshit, Karen Flannagan, N. V. Adsay, M. Pasca di Magliano. Journal of Clinical Investigation, 2012

709 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2d88928e4159bccb41032be7950fb3b714003dd6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Randy L. Johnson
2. Carol S. Lim
3. A. Kapoor
4. Sujun Hua
5. R. DePinho
6. Zhiyong Wang
7. Minoru Kanehisa
8. Keun-Joon Park

In Oncology

1. Randy L. Johnson
2. R. DePinho

Citations in the corpus

• Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer (2014, positive): “To model anti-Ras therapy, we and others have generated an inducible Kras GEM PDAC model and established that extinction of Kras induced rapid tumor regression, highlighting the potential clinical utility of targeting oncogenic KRAS in pancreatic cancer (Collins et al., 2012; Ying et al., 2012).”